Literature DB >> 6214279

Studies on the kinetics of plasminogen activation by tissue plasminogen activator.

M Rånby.   

Abstract

The steady-state rate of plasminogen activation by tissue plasminogen activator has been determined at various plasminogen concentrations. A plasmin substrate method similar to that presented by Christensen and Müllertz (Biochim. Biophys. Acta 480 (1977) 257-281) was used. The reaction was studied using one-chain type and two-chain type tissue plasminogen activator, N-terminal glutamic acid and N-terminal lysine plasminogen in the presence and in the absence of fibrin (eight studies). The kinetic data were fitted to a general Wong-Hanes equation and the simplest equation with significant parameters was found. In the absence of fibrin N-terminal glutamic acid plasminogen activation obeyed the Michaelis-Menten rate equation (Km 4.9 and 7.6 micro M and kcat 0.0013 and 0.0078 s-1 for one-chain type and two-chain type tissue plasminogen activator, respectively. In the absence of fibrin the activation of N-terminal lysine plasminogen activation failed to obey the Michaelis-Menten rate equation. Fibrin was found to stimulate greatly (up to 1000-fold) the steady-state activation rate. A theory for the fibrin stimulating mechanism is presented.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214279     DOI: 10.1016/0167-4838(82)90068-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  49 in total

1.  The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity.

Authors:  Denis Gingras; Dominique Labelle; Carine Nyalendo; Dominique Boivin; Michel Demeule; Chantal Barthomeuf; Richard Béliveau
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

2.  Positive co-operative binding at two weak lysine-binding sites governs the Glu-plasminogen conformational change.

Authors:  U Christensen; L Mølgaard
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

3.  Binding of human plasminogen to basement-membrane (type IV) collagen.

Authors:  M S Stack; T L Moser; S V Pizzo
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

4.  Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N.

Authors:  Mercy O Quagraine; Fulong Tan; Hironori Tamei; Ervin G Erdös; Randal A Skidgel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

5.  Plasminogen activators in ischemic stroke: introduction.

Authors:  Gregory J del Zoppo
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

6.  Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.

Authors:  J M Edelberg; M Weissler; S V Pizzo
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

7.  Localization of the binding site of tissue-type plasminogen activator to fibrin.

Authors:  A Ichinose; K Takio; K Fujikawa
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 8.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

Review 9.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

10.  Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.

Authors:  E J Dunn; H Philippou; R A S Ariëns; P J Grant
Journal:  Diabetologia       Date:  2006-03-16       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.